The Word Health Organization (WHO) reports that more than 3.6 million people are diagnosed with solid malignant tumors every year in the US and EU. Literature over several decades documents how a complete tumor resection and tumor - specific debulking in cytoreductive surgery can significantly improve prognosis. However, a predominant challenge for surgeons during procedures has been the limitations of visual inspection and digital palpation to distinguish tumors, tumor remnants and metastases from healthy tissue.

SurgVision brings a revolution in surgery by enhancing the surgeon's vision with use of innovative near-infrared fluorescence molecular imaging. The company's proprietary technology - internally termed Multi-Spectral Normalized Imaging (MSNI) - is a combination of advanced imaging technology and highly expert know-how that make fluorescence imaging of molecular probes significantly robust and accurate for clinical use.

The technology is based on the exposure of the identified tumor tissue to electromagnetic energy, in particular, light. This uses safe energies at multiple wavelengths and utilizes a combination of optical detection and processing techniques. Image formation is then performed using mathematical processing of the different spectral bands captured to yield - in video rate speeds - accurate (corrected) fluorescence color and superimposed images.

By accurately handling the strong non-linear dependence of light intensity on tissue and the propagation characteristics, accurate error-free tissue images can be reconstructed with a resolution that is variable and can be better than 20 microns. The technology allows safe power delivery in tissue by operating with low light power levels, well within established ANSI standards for use of light with humans and human tissue.

A further aspect of the invention, contained in the Company's IP, is the operation within the molecular imaging regime after the administration of a molecular probe with specificity to a disease bio-marker. This makes the method suitable for next generation clinical imaging applications. Importantly, the energy spectrum used can be absorbed by a variety of probes and small particles, some already approved for clinical use, which can enable practical visualization of specific biomarkers.

Please find below a list of scientific publications describing SurgVision's technology in full or in part.

van Dam, Gooitzen M., et al. "Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-[alpha] targeting: first in-human results." Nature medicine 17.10 (2011): 1315-1319. Link

Glatz, Jürgen, et al. "Concurrent video-rate color and near-infrared fluorescence laparoscopy." Journal of biomedical optics 18.10 (2013): 101302-101302. Link

Garcia-Allende, P. Beatriz, et al. "Towards clinically translatable NIR fluorescence molecular guidance for colonoscopy." Biomedical optics express 5.1 (2014): 78-92. Link

Glatz, Jürgen, et al. "Near-infrared fluorescence cholangiopancreatoscopy: initial clinical feasibility results." Gastrointestinal endoscopy 79.4 (2014): 664-668. Link

Koch, Maximilian, et al. "Video-rate optical flow corrected intraoperative functional fluorescence imaging." Journal of biomedical optics 19.4 (2014): 046012-046012. Link